Menlo Therapeutics Inc. is a specialty dermatology company with an approved, commercial product, AMZEEQ (FMX101), a topical foam (minocycline 4%) for the treatment of moderate-to-severe acne. Additionally, the Company has several late-stage product candidates including FMX103 (minocycline 1.5%), which is under NDA review for the treatment of rosacea, and FCD105 (minocycline 3% and adapalene 0.3%), which is in Phase 2 trials for the treatment of moderate-to-severe acne. AMZEEQ utilizes the Company’s proprietary Molecule Stabilizing Technology (MST) that is also being used to develop the Company’s current product candidates, FMX103 and FCD105.